Key Points
- CEO Phillip Chan purchased 3,774 Cytosorbents shares at $6.00 each, investing $22,644 and increasing his direct ownership by 3.88% to 100,996 shares.
- Cytosorbents reported quarterly revenue of $9.63 million and an EPS loss of $0.07, outperforming analyst estimates, but remains unprofitable with a negative net margin of 48.94%.
- Analyst sentiment is mixed—one analyst rates the stock Buy, one Hold and one Sell—resulting in a consensus “Hold” rating.
Cytosorbents Corporation (NASDAQ:CTSO - Get Free Report) CEO Phillip Chan purchased 3,774 shares of the firm's stock in a transaction dated Tuesday, September 15th. The stock was bought at an average cost of $6.00 per share, for a total transaction of $22,644.00. Following the acquisition, the chief executive officer directly owned 100,996 shares in the company, valued at approximately $605,976. The trade was a 3.88% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.
Cytosorbents Stock Performance
NASDAQ CTSO opened at $5.73 on Thursday. Cytosorbents Corporation has a 52-week low of $5.13 and a 52-week high of $20.40. The company has a debt-to-equity ratio of 4.70, a quick ratio of 0.50 and a current ratio of 0.66. The company has a market capitalization of $18.05 million, a P/E ratio of -0.99 and a beta of 1.34. The company has a fifty day moving average of $7.15 and a 200-day moving average of $9.77.
Cytosorbents (NASDAQ:CTSO - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical research company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.73. The company had revenue of $9.63 million during the quarter, compared to analyst estimates of $9.38 million. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%. As a group, equities research analysts predict that Cytosorbents Corporation will post -4.4 EPS for the current fiscal year.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Cytosorbents in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Cytosorbents has a consensus rating of "Hold" and an average price target of $107.50.
Get Our Latest Analysis on CTSO
About Cytosorbents
(
Get Free Report)
Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company's flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient's blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.
CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
